PDF factsheet
      Z

niacin in cardiovascular prevention for all type of patients, clinical trials results

clofibtate+niacin versus placebo
Carlson (Stockholm), 1977
clofibrate, 1 g twice daily, and nicotinic acid 1 g three times daily
versus
control
survivors of a myocardial infarction below 70 years of age open
Follow-up duration: 5 years
Sweden
colestipol-niacin versus placebo
CLAS, 1987
colestipol + niacin
versus
placebo
nonsmoking men aged 40 to 59 years with previous coronary bypass surgerydouble blind
Follow-up duration: 2 years
niacin versus control
VA drugs, 1968
niacin
versus
double blind
Follow-up duration: 3.2 years
niacin versus ezetimibe
ARBITER 6-HALTS (niacin vs ezetimibe), 2009
NCT00397657
extended-release niacin 1 g/d, titrated to max tolerable dose up to 2 g/d (HDL-focused strategy)
versus
ezetimibe 10 mg/d (LDL-focused strategy)
patients with known coronary or vascular disease or coronary risk equivalentsopen
Follow-up duration: 14 months
US
niacin versus placebo
CDP niacin, 1975
niacin 3 mg/d
versus
placebo
Hommes, de 30 à 64 ans double blind
Follow-up duration: 6.2 years
niacin versus placebo (on top statin)
AIM-HIGH, 2011
NCT00120289
high-dose, extended-release niacin in gradually increasing doses up to 2000 mg daily (+ simvastatin)
versus
placebo
patients with a history of cardiovascular disease, high triglycerides, and low levels of HDL cholesteroldouble blind
Follow-up duration: 32 months
US, Canada
HPS 2-Thrive,
NCT00461630
2 g of extended-release niacin and 40 mg of laropiprant
versus
placebo
patients with vascular diseasedouble blind
Follow-up duration: 3.9y (median)
UK, Scandinavia, China
Oxford Niaspan Study, 2009
NCT00232531
niacin 2g daily (added to statin therapy)
versus
placebo (statins alone)
patients with low HDL-C (<40 mg/dl) and either a type 2 diabetes with coronary heart disease or a carotid/peripheral atherosclerosisdouble blind
Follow-up duration: 1 year
USA
ARBITER 2, 2009
long-acting niacin target dose of 1 g/day (added to statin therapy)
versus
placebo
patients with known coronary artery disease and well controlled on statin therapydouble blind
Follow-up duration: 1 y
USA
HATS, 2001
simvastatin plus niacin
versus
placebo
patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels double blind
Follow-up duration: 3 y
USA, Canada
niacin+colestipol versus control
UCSF SCOR, 1990
Niacin 0–7.5 g colestipol 15–20 g
versus
Conventional therapy
patients with heterozygous familial hypercholesterolemia
Follow-up duration: 26 months
niacin+colestipol versus placebo
FATS, 1990
niacin (1 g four times a day) and colestipol (10 g three times a day)
versus
placebo (or colestipol if the low-density lipoprotein [LDL] cholesterol level was elevated)
men no more than 62 years of age with apolipoprotein B levels greater than or equal to 125 mg per deciliter, documented coronary artery disease, and a family history of vascular diseasedouble-blind
Follow-up duration: 2.5 years
niacin+ezetimibe versus simvastatin+ezetimibe
Guyton, 2008
Niacin 2 g ezetimibe 10 mg simvastatin 20 mg
versus
Ezetimibe 10 mg simvastatin 20 mg
patients with type IIa or IIb hyperlipidemiadouble-blind
Follow-up duration: 24 weeks
strategy to increase HDL cholesterol versus placebo
AFREGS, 2005
Niacin 0.25–3 g gemfibrozil 1.2 g cholestyramine 2 g
versus
placebo
military retirees younger than 76 years of age with low HDL cholesterol levels and angiographically evident coronary diseasedouble-blind
Follow-up duration: 30 months

  Options


in first

in second

  Filter